FDA Clears Sagimet's IND for Phase 3 Acne Trial, Paving Way for H2 2026 Start
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet received FDA 'Study May Proceed' clearance for its IND on denifanstat in moderate to severe acne, allowing the Phase 3 trial to initiate in H2 2026. This follows the Q2 2026 results and strategic pivot toward acne, with $257.6M in cash funding operations through the trial. The clearance removes a key regulatory hurdle and validates the acne program's path forward. The Phase 3 trial start is now confirmed for the second half of 2026.
At the time of this announcement, SGMT was trading at $9.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $574.5M. The 52-week trading range was $4.50 to $10.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.